Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
- Citation:
- J Thorac Oncol vol 3 (4) 417-21
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA31946, CA33601, R21CA83689
- Corr. Author:
- Authors:
- Robert A Kratzke Xiaofei Wang Long Wong Marian G Kratzke Mark R Green Everett E Vokes Nicholas J Vogelzang Hedy L Kindler Jeffrey A Kern
- Networks:
- Study
- CALGB-159904
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- N/A
- Keywords:
- Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Azacitidine, Cyclin-Dependent Kinase Inhibitor p16, DNA Methylation, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Mesothelioma, Middle Aged, Polymerase Chain Reaction, Prognosis, Survival Rate